Syed O Hasan
Examiner (ID: 9396, Phone: (571)272-0990 , Office: P/3747 )
Most Active Art Unit | 3747 |
Art Unit(s) | 3783, 3747 |
Total Applications | 907 |
Issued Applications | 710 |
Pending Applications | 53 |
Abandoned Applications | 143 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 18980100
[patent_doc_number] => 11905260
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-02-20
[patent_title] => N'-(1-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound
[patent_app_type] => utility
[patent_app_number] => 18/486813
[patent_app_country] => US
[patent_app_date] => 2023-10-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4006
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 8
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18486813
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/486813 | N'-(1-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound | Oct 12, 2023 | Issued |
Array
(
[id] => 18980102
[patent_doc_number] => 11905262
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-02-20
[patent_title] => N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-2-naphthimidamide as an antimicrobial compound
[patent_app_type] => utility
[patent_app_number] => 18/379024
[patent_app_country] => US
[patent_app_date] => 2023-10-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4021
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 8
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18379024
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/379024 | N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-2-naphthimidamide as an antimicrobial compound | Oct 10, 2023 | Issued |
Array
(
[id] => 18806990
[patent_doc_number] => 20230381323
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-30
[patent_title] => RELEASABLE CONJUGATES
[patent_app_type] => utility
[patent_app_number] => 18/234142
[patent_app_country] => US
[patent_app_date] => 2023-08-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48481
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 319
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18234142
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/234142 | RELEASABLE CONJUGATES | Aug 14, 2023 | Pending |
Array
(
[id] => 18753821
[patent_doc_number] => 20230357119
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-09
[patent_title] => PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF CARBAPROSTACYCLIN ANALOGUES
[patent_app_type] => utility
[patent_app_number] => 18/325214
[patent_app_country] => US
[patent_app_date] => 2023-05-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16703
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18325214
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/325214 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF CARBAPROSTACYCLIN ANALOGUES | May 29, 2023 | Pending |
Array
(
[id] => 18869767
[patent_doc_number] => 11857547
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-02
[patent_title] => Compositions and methods for opioid antagonist delivery
[patent_app_type] => utility
[patent_app_number] => 18/195142
[patent_app_country] => US
[patent_app_date] => 2023-05-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 12096
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18195142
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/195142 | Compositions and methods for opioid antagonist delivery | May 8, 2023 | Issued |
Array
(
[id] => 18753868
[patent_doc_number] => 20230357176
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-09
[patent_title] => PROCESS-SCALE SYNTHESIS OF UROLITHIN A
[patent_app_type] => utility
[patent_app_number] => 18/138357
[patent_app_country] => US
[patent_app_date] => 2023-04-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8057
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18138357
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/138357 | PROCESS-SCALE SYNTHESIS OF UROLITHIN A | Apr 23, 2023 | Pending |
Array
(
[id] => 18597183
[patent_doc_number] => 20230271976
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => OPIOID RECEPTOR MODULATORS
[patent_app_type] => utility
[patent_app_number] => 18/297081
[patent_app_country] => US
[patent_app_date] => 2023-04-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47420
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -46
[patent_words_short_claim] => 134
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18297081
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/297081 | OPIOID RECEPTOR MODULATORS | Apr 6, 2023 | Pending |
Array
(
[id] => 18496007
[patent_doc_number] => 20230218534
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => SYSTEMS AND METHODS FOR INCREASING STABILITY OF DRONABINOL COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 18/090722
[patent_app_country] => US
[patent_app_date] => 2022-12-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5460
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18090722
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/090722 | SYSTEMS AND METHODS FOR INCREASING STABILITY OF DRONABINOL COMPOSITIONS | Dec 28, 2022 | Pending |
Array
(
[id] => 18364538
[patent_doc_number] => 20230146129
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-11
[patent_title] => HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
[patent_app_type] => utility
[patent_app_number] => 18/089065
[patent_app_country] => US
[patent_app_date] => 2022-12-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25840
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18089065
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/089065 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Dec 26, 2022 | Pending |
Array
(
[id] => 18281354
[patent_doc_number] => 20230096826
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-30
[patent_title] => EFFICIENT NEW PROCESS FOR SYNTHESIS OF 2-AMINO-5-CHLORO-N-,3-DIMETHYLBENZAMIDE
[patent_app_type] => utility
[patent_app_number] => 18/070827
[patent_app_country] => US
[patent_app_date] => 2022-11-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11970
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18070827
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/070827 | EFFICIENT NEW PROCESS FOR SYNTHESIS OF 2-AMINO-5-CHLORO-N-,3-DIMETHYLBENZAMIDE | Nov 28, 2022 | Pending |
Array
(
[id] => 18948121
[patent_doc_number] => 11891402
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-06
[patent_title] => Compositions and methods for treating cancer
[patent_app_type] => utility
[patent_app_number] => 18/058655
[patent_app_country] => US
[patent_app_date] => 2022-11-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 53
[patent_figures_cnt] => 58
[patent_no_of_words] => 60983
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18058655
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/058655 | Compositions and methods for treating cancer | Nov 22, 2022 | Issued |
Array
(
[id] => 18725750
[patent_doc_number] => 20230339954
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => Heterocyclic Compounds as RET Kinase Inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/992049
[patent_app_country] => US
[patent_app_date] => 2022-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38368
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17992049
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/992049 | Heterocyclic Compounds as RET Kinase Inhibitors | Nov 21, 2022 | Pending |
Array
(
[id] => 18285537
[patent_doc_number] => 20230101009
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-30
[patent_title] => THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA
[patent_app_type] => utility
[patent_app_number] => 17/991558
[patent_app_country] => US
[patent_app_date] => 2022-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10474
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17991558
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/991558 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | Nov 20, 2022 | Pending |
Array
(
[id] => 18285220
[patent_doc_number] => 20230100692
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-30
[patent_title] => SYNTHETIC PROCESS AND NOVEL INTERMEDIATES
[patent_app_type] => utility
[patent_app_number] => 17/990939
[patent_app_country] => US
[patent_app_date] => 2022-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8381
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17990939
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/990939 | SYNTHETIC PROCESS AND NOVEL INTERMEDIATES | Nov 20, 2022 | Pending |
Array
(
[id] => 18915756
[patent_doc_number] => 11878022
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-23
[patent_title] => Hydrochlorothiazide compositions
[patent_app_type] => utility
[patent_app_number] => 18/053197
[patent_app_country] => US
[patent_app_date] => 2022-11-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12312
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18053197
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/053197 | Hydrochlorothiazide compositions | Nov 6, 2022 | Issued |
Array
(
[id] => 18351576
[patent_doc_number] => 20230139687
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => Preparation Methods and Uses of Purified Fulvic Acid
[patent_app_type] => utility
[patent_app_number] => 18/050743
[patent_app_country] => US
[patent_app_date] => 2022-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1202
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18050743
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/050743 | Preparation Methods and Uses of Purified Fulvic Acid | Oct 27, 2022 | Pending |
Array
(
[id] => 18350135
[patent_doc_number] => 20230138246
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => USE OF DIHYDROBERBERINE OR ITS DERIVATIVES FOR ANTI-AGING
[patent_app_type] => utility
[patent_app_number] => 17/975028
[patent_app_country] => US
[patent_app_date] => 2022-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5249
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17975028
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/975028 | USE OF DIHYDROBERBERINE OR ITS DERIVATIVES FOR ANTI-AGING | Oct 26, 2022 | Pending |
Array
(
[id] => 18211345
[patent_doc_number] => 20230057608
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-23
[patent_title] => METHODS FOR THE SYNTHESIS OF ACTIVATED ETHYLFUMARATES AND THEIR USE AS INTERMEDIATES
[patent_app_type] => utility
[patent_app_number] => 17/972220
[patent_app_country] => US
[patent_app_date] => 2022-10-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11420
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17972220
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/972220 | METHODS FOR THE SYNTHESIS OF ACTIVATED ETHYLFUMARATES AND THEIR USE AS INTERMEDIATES | Oct 23, 2022 | Pending |
Array
(
[id] => 19456718
[patent_doc_number] => 12097185
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-24
[patent_title] => Compositions comprising ciprofloxacin and celecoxib
[patent_app_type] => utility
[patent_app_number] => 18/047289
[patent_app_country] => US
[patent_app_date] => 2022-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 8393
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18047289
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/047289 | Compositions comprising ciprofloxacin and celecoxib | Oct 17, 2022 | Issued |
Array
(
[id] => 18953571
[patent_doc_number] => 20240041898
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2024-02-08
[patent_title] => NEUROSTEROIDS AND ENANTIOMERS THEREOF FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 18/046244
[patent_app_country] => US
[patent_app_date] => 2022-10-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11179
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18046244
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/046244 | NEUROSTEROIDS AND ENANTIOMERS THEREOF FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE CONDITIONS | Oct 12, 2022 | Pending |